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OBJECTIVES This study was designed to examine whether the occurrence of left ventricular hypertrophy
(LVH) in moderate to severe essential hypertension (EHT) was associated with alteration in
peripheral sympathetic drive.
BACKGROUND In hypertension, LVH is an independent predictor of increased morbidity and mortality. The
reported mechanisms leading to LVH remain unclear but include hemodynamic and humoral
factors. The sympathetic nervous system may be important, particularly as catecholamines
have been shown to have trophic properties. We tested the hypothesis that sympathetic
activity measured using microneurography could be different in patients with hypertension
depending on the presence of LVH.
METHODS We examined 28 subjects with moderate to severe EHT (stages 2 to 3; Joint National
Committee [JNC]-VI classification). Fourteen had echocardiographic evidence of LVH
(EHT  LVH), while the other 14 subjects (EHT) did not. Subjects were matched in terms
of age, body mass index and levels of arterial blood pressure. Peripheral muscle sympathetic
nerve activity was measured from both multiunit bursts (MSNA) and single unit (s-MSNA)
vasoconstrictor impulses via the peroneal nerve.
RESULTS The mean frequency of s-MSNA and MSNA was greater in the EHT  LVH group
than it was in the EHT group (mean  SEM; 75.9  6.9 impulses/100 beats vs. 52.1 
2.9 impulses/100 beats, p  0.001 and 64.2  5.7 bursts/100 beats vs. 48.9  2.8 bursts/100
beats, p  0.05).
CONCLUSIONS These results indicate that, in subjects with moderate to severe hypertension, the pres-
ence of LVH is associated with higher sympathetic discharge, evidenced by an increase in
unitary firing frequency and also by fiber recruitment. (J Am Coll Cardiol 2001;38:1711–7)
© 2001 by the American College of Cardiology
In patients with hypertension, the occurrence of left ven-
tricular hypertrophy (LVH) has been associated with an
increase in mortality from all cardiovascular causes (1–4).
However, not all subjects go on to develop LVH, and the
reasons for this remain undetermined. The development of
LVH has been attributed to many factors, including raised
arterial pressure levels (resulting in increased myocardial
workload) and growth-promoting substances such as angio-
tensin II, insulin-like growth factor-1 and circulating cat-
echolamines (5–10).
In essential hypertension (EHT), the elevated arterial
pressure has been associated with increased central sympa-
thetic output to the heart, kidney and skeletal muscles
(11–13). In humans, a direct assessment of sympathetic
activity can be performed using the technique of microneu-
rography. This technique measures muscle sympathetic
nerve activity (MSNA) via the assessment of the mean
frequency of multiunit MSNA bursts (14,15) or from single
unit vasoconstrictor activity (s-MSNA) (16,17).
It has been suggested that the severity of hypertension is
related to the magnitude of increased sympathetic drive
(15). However, other studies have not demonstrated this
relationship (18,19), and, more recently, we have shown
that, in stage 1 hypertensive disease, the peripheral sympa-
thetic drive is, in fact, higher than that found in the more
severe degrees of hypertension (16). In accounting for these
differences, one should bear in mind that in the earlier study
(15) the presence LVH was not taken into account.
Thus, it remains unknown whether hypertensive patients
who have developed LVH have altered sympathetic drive
compared with those without LVH who have similar blood
pressure levels. Indeed, it is known that patients with
hypertension who have peripheral vascular disease have a
greater degree of LVH than those without LVH (20) and
that increased sympathetic drive enhances vascular hyper-
trophy (10). This supports the hypothesis that patients with
hypertension and end-organ damage may have evidence of
more severe and widespread sympathetic hyperactivity.
Therefore, this investigation was designed to see whether
in EHT the presence of LVH was associated with altered
central sympathetic drive to the periphery at rest. In
addition to multiunit microneurographic recordings, single
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unit discharge was obtained as this allows further insight
into the mechanisms of central autonomic control. Two
groups of patients with hypertension were examined, either
with or without LVH, and they were closely matched in
terms of age, body weight and, in particular, arterial blood
pressure levels.
METHODS
Subjects. The study involved Caucasian patients with
newly diagnosed EHT who were examined between January
1998 and May 1999. The study group was recruited from
among 34 patients; in 6 patients it was not possible to obtain
stable microneurographic data. All patients were screened
by history, physical and laboratory examination. Patients
were excluded if there was evidence of secondary hyperten-
sion, arrhythmia or chronic disease that may influence the
autonomic nervous system. Fourteen patients (six male) had
hypertension complicated by LVH (EHT  LVH), and
their arterial blood pressure values, based on the average of
at least three readings taken on separate occasions, indicated
a severity of hypertension within stage 2 or 3 of the Joint
National Committee (JNC)-VI classification (21), as sum-
marized in the following text.
Stage 1: Systolic blood pressure of 140 to 159 mm Hg or
diastolic blood pressure of 90 to 99 mm Hg.
Stage 2: Systolic blood pressure of 160 to 179 mm Hg or
diastolic blood pressure of 100 to 109 mm Hg.
Stage 3: Systolic blood pressure of 180 mm Hg or
diastolic blood pressure of 110 mm Hg.
Over the same period of time, a second group of 14 patients
(9 male) with EHT without signs of LVH were studied,
and these were matched in terms of age, body weight, body
mass index and levels of arterial blood pressure.
Electrocardiographic voltage criteria were used to identify
subjects with suspected LVH, and left ventricular dimen-
sions were measured using two-dimensional M-mode echo-
cardiography (Toshiba Powervision SSA-380A, Toshiba
Corp., Japan). Using American Society of Echocardiogra-
phy recommendations (22), measurements of end-diastolic
posterior wall thickness (PW), left ventricular internal
diameter (LVID) and intraventricular septal thickness (IVS)
were determined and considered to represent LVH if
measures of PW or IVS exceeded 11 mm. Left ventricular
mass (LVM) was calculated according to the Penn conven-
tion (23) using the equation: LVM(g)  1.04 [(IVS 
LVID  PW)3  (LVID)3]  13.6 and, to account for
body surface area, left ventricular mass index (LVMI) was
derived.
Of the 14 patients with EHT  LVH, 8 had stage 2 and
6 had stage 3 disease. Due to the severity of disease, some
individuals had already been commenced on oral antihyper-
tensive therapy (between two and four months) before
taking part in the study. It was felt unethical to perform a
prolonged washout period before these studies, so treatment
was only omitted on the study day. Of these 14 patients, 6
were receiving treatment that consisted of diuretics (n  2),
the beta-blocking agent atenolol (n  2), angiotensin-
converting enzyme inhibitors (n  3) and calcium antago-
nists (n  1). The 14 patients with EHT (seven each with
stage 2 and stage 3 disease) who did not have evidence of
LVH were examined before commencing antihypertensive
therapy.
General protocol. Under the approval of St. James’s Uni-
versity Hospital Ethics Committee, subjects provided in-
formed written consent to the investigation. All subjects
were studied between the hours of 9 AM and 12:00 midday
and were asked to avoid nicotine and caffeine products for
12 h and alcohol and strenuous exercise for 24 h before the
investigation. Subjects maintained a normal dietary intake
of sodium, and they were requested to have had a light
breakfast and to empty their bladder before commencing
the study.
During each session, subjects were studied in the semisu-
pine position. Measurements were made in a darkened
laboratory in which the temperature was constant at 22 to
24°C. Heart rate and arterial blood pressure were monitored
and recorded using a standard electrocardiogram and a
Finapres device (Model 2300; Ohmeda, Hatfield, Herts,
United Kingdom) applied to the middle finger at the level of
the heart. A pneumograph consisting of a corrugated rubber
tube connected to a pressure transducer was used to monitor
and record respiration. Subjects were asked to relax and not
speak for 10 min so as to reach a steady state, after which
time hemodynamic and microneurographic data were ob-
tained for repeated baseline resting measurements of at least
5-min duration.
Microneurography. Postganglionic muscle sympathetic
nerve activity was recorded from the right peroneal nerve as
previously described in detail (14,16). Briefly, the neural
signal was amplified (50,000), and, for the purpose of
generating bursts representing multiunit discharge, the sig-
nal was filtered (bandwidth of 700 to 2,000 Hz) and
integrated (time constant 0.1 s). The output of action
potentials and bursts from this assembly were passed to a
Abbreviations and Acronyms
EHT  essential hypertension
EHT  LVH  essential hypertension with left
ventricular hypertrophy
IVS  intraventricular septal thickness
JNC  Joint National Committee
LVH  left ventricular hypertrophy
LVID  left ventricular internal diameter
LVM  left ventricular mass
LVMI  left ventricular mass index
MSNA  multiunit muscle sympathetic nerve
activity
PW  end-diastolic posterior wall thickness
s-MSNA  single-unit muscle sympathetic nerve
activity
1712 Greenwood et al. JACC Vol. 38, No. 6, 2001
Hypertensive LVH and Peripheral Sympathetic Drive November 15, 2001:1711–7
data-acquisition system (FASTDAQ, Lectromed UK Ltd.,
Letchworth Garden City, Herts, United Kingdom) for
on-line monitoring and storage using a minicomputer
(Elonex UK Ltd., Bradford, United Kingdom). The
FASTDAQ system digitized the action potentials at 12,000
samples/s and all other data channels at 2,000 samples/s
(8 bits). Long-term storage was achieved using a high-
capacity drive (Iomega zip drive, Iomega Europe GmbH,
Freiburg, Germany).
With the exploring electrode in the nerve, electrical
stimulation (0.1 to 1.0 V, 1 Hz, 0.2 ms) caused muscular
twitches without paraesthesia. Multiunit muscle sympa-
thetic nerve activity was differentiated from skin sympa-
thetic activity and afferent activity by previously accepted
criteria (14). Single units were sought by repeatedly making
tiny adjustments to the exploring electrode position. When
a unit was identified in the raw action potential neurogram
as being different in height from other concomitant units (if
present), it was further scrutinized to confirm it had
vasoconstrictor properties, as described in the section
entitled “Other procedures.” Fast monitor sweep and an
on-line storage oscilloscope were then used to confirm the
presence of a single unit by demonstrating consistency in
action potential morphology as previously described (16,17).
Other procedures. Only vasoconstrictor activity was ac-
cepted and examined, the criteria of acceptance being
appropriate responses to spontaneous changes in arterial
blood pressure, the Valsalva maneuver and isometric hand-
grip exercise, as previously described (16,17). Briefly, during
Valsalva, sympathetic activity increased during the latter
part of phase II or phase III and decreased during phase IV
(increase and overshoot of blood pressure). Isometric hand-
grip exercise, performed using a dynamometer (MIE Med-
ical Research Ltd., Leeds, United Kingdom) produced a late
increase in arterial blood pressure, sympathetic neural activ-
ity and calf vascular resistance. Calf vascular resistance was
determined from the product of mean arterial pressure on
the mean of at least six measurements of calf blood flow in
the left leg using strain-gauge plethysmography (DE
Hokansen Inc., Bellevue, Washington). In each subject the
resting mean frequencies of s-MSNA impulses and MSNA
bursts were obtained simultaneously.
Data analysis. Without knowledge of the patient
diagnosis, data analysis was performed off-line by a single
experienced operator using signal-processing software
(FASTDAQ, Lectromed UK Ltd.). Mean data from at
least three baseline time periods were analyzed. An elec-
tronic discriminator was used to count the spikes of
s-MSNA and the R-wave of the electrocardiogram (Fig. 1).
The former was quantified as mean frequency of impulses/
min and impulses/100 cardiac beats. The bursts of MSNA
on the mean voltage neurogram were identified by inspec-
tion, being defined by amplitude when the signal-to-noise
ratio was 3, and they were quantified as mean number of
bursts/min and bursts/100 cardiac beats. Neural activity was
expressed both per min and per 100 cardiac beats as it is
understood that there is a complex relationship between
heart rate and sympathetic discharge frequency, and the
latter expression avoids any interference by the length of the
cardiac cycle (24).
Statistics. Two-way analysis of variance (ANOVA) with
Bonferroni multiple post-test comparisons were used to
compare data between the two groups. The least square
technique was used for assessing the linear relationship
between variables. Values of p 0.05 were considered
statistically significant. Data were presented as mean 
SEM.
RESULTS
The demographic details of the two matched groups are
shown in Table 1. There was no significant difference in
age, body weight, body mass index, heart rate or arterial
blood pressure between the groups.
Figure 1. Example of recordings from a patient with hypertension. From
above and moving down are shown the electrocardiogram (ECG), respi-
ratory movements (Resp), Finapress blood pressure (FBP), multiunit
muscle sympathetic nerve activity (Bursts) and action potentials (AP in
V). The single-unit muscle sympathetic nerve activity is counted from
APs of the same profile and amplitude (tallest unit in this example) to
derive the mean frequency of central vasoconstrictor sympathetic neural
discharge. The burst count may include a variable number of units with
different profiles.
Table 1. Demographic Details of the Two Subject Groups
Subjects EHT EHT  LVH p Value*
Number (men) 14 (9) 14 (6)
Disease stage 2 (stage 3) 7 (7) 8 (6)
Age (yrs) 53  1.8 55  2.4 NS
Weight (kg) 84  4.0 84  3.3 NS
Body mass index (kg/m2) 30  1.0 30  1.3 NS
Heart rate (beats/min) 74  2.6 67  2.1 NS
Arterial pressure (mm Hg)
Mean 128  3.4 125  3.2 NS
Systolic 173  4.5 174  6.6 NS
Diastolic 107  4.1 101  2.6 NS
*Two-way analysis of variance (Bonferoni post-test analysis), no significant interac-
tion (p  0.7).
EHT  essential hypertension; LVH  left ventricular hypertrophy; NS 
nonsignificant.
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As expected, there was a significant positive correlation
(r) for resting s-MSNA and MSNA with the subjects age (r
at least 0.42 and at most 0.59; p  0.0002). However, there
was no significant correlation within any group (consistently
r  0.38, p  0.09) between resting sympathetic discharge
(s-MSNA or MSNA) and the levels of resting arterial blood
pressure (systolic, diastolic or mean pressure) or heart rate.
Respectively, for the EHT LVH and the EHT groups,
posterior wall thickness was 13 0.8 mm and 10 0.3 mm
(p  0.05); interventricular septal thickness was 12 
0.8 mm and 10  0.3 mm (p  0.05), and end-diastolic
volumes were 124  12.4 ml and 127  15.8 ml (p  0.8).
The estimated LVM in the EHT LVH group was 301
26.6 g and in the EHT group was 215  19 g (p  0.05),
and the values for LVMI when indexed by body surface area
were 155  13 g/m2 and 113  10.9 g/m2 for the two
groups, respectively (p  0.05). Using two-way ANOVA,
no significant interaction was found between any of these
variables (p  0.3).
Resting s-MSNA in EHT  LVH was greater than that
in EHT; on average this represented a 34% and a 46%
increase when activity was expressed per minute and per 100
cardiac beats (Fig. 2). The group mean frequency of
s-MSNA in EHT  LVH versus EHT was 51.1  5.3
impulses/min versus 38.1  2.4 impulses/min (p  0.05)
and 75.9  6.9 impulses/100 beats versus 52.1  2.9
impulses/100 beats (p  0.001). In addition, the group of
EHT  LVH had greater resting MSNA than the EHT
group (Fig. 3), respectively; on average this represented a
14% and 31% increase when activity was expressed per
minute and per 100 cardiac beats. The group mean fre-
quency of MSNA in EHT LVH versus EHT was 40.6
2.5 bursts/min versus 35.5  2.1 bursts/min (p  0.05) and
64.2  5.7 bursts/100 beats versus 48.9  2.8 bursts/100
beats (p  0.05). Two-way ANOVA of these variables
showed there was no significant interaction (p  0.15).
When only the 22 untreated patients were considered (8 in
the EHT  LVH group vs. 14 in the EHT group), the
overall findings were unaltered in that the LVH group still
had significantly greater sympathetic discharge compared
with the non-LVH group. Within the group of EHT 
LVH, there was no significant difference in any measure of
sympathetic discharge between those who were treated and
those untreated (Figs. 2 and 3). Finally there was a signif-
icant correlation between both s-MSNA and MSNA
(quantified per 100 cardiac beats) and LVMI (always p 
0.05; r  0.48 and r  0.46, respectively).
DISCUSSION
This is the first evidence that the mean resting frequency of
peripheral sympathetic vasoconstrictor discharge in moder-
ate to severe hypertension was greater in those patients with
LVH compared with those without LVH. This relative
sympathetic hyperactivity reflected an increased central
output at rest and was not caused by differences in arterial
blood pressure, age or body weight. These findings allow us
to hypothesize that patients with relatively higher central
sympathetic output may be more likely to develop LVH
than those with equivalent severity of hypertension who
have lower sympathetic output.
Microneurography. Microneurography is a well-established
technique that has been used successfully in the assessment of
peripheral sympathetic activity (14). Previous studies have
examined the frequency and incidence of MSNA bursts
derived from multiunit recordings but have not been specific to
any of the individual action potentials that constitute the burst.
Despite the difficulty of establishing that every unit within a
burst has a vasoconstrictor role, there is a wealth of evidence to
Figure 2. Scatter-graph showing the mean frequency of single-unit muscle
sympathetic nerve activity (s-MSNA) in essential hypertensives with left
ventricular hypertrophy (LVH) (triangles) and without LVH (squares).
Open triangles  those subjects receiving therapy; bars  the group
mean. *p  0.001 (two-way analysis of variance). NS  nonsignificant.
Figure 3. Scatter-graph showing the mean frequency of multiunit muscle
sympathetic nerve activity (MSNA) in essential hypertensives with left
ventricular hypertrophy (LVH) (triangles) and without LVH (squares).
Open triangles  those subjects receiving therapy; Bars  the group
mean. †p  0.05 (two-way analysis of variance). NS  nonsignificant.
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suggest that patients with hypertension have a greater fre-
quency of MSNA bursts than properly matched normotensive
subjects (15,25–27).
More recently, recordings of single unit muscle sympa-
thetic discharge have been obtained from normotensive and
hypertensive subjects (16,17). Though more difficult to
obtain than MSNA bursts, the advantage of directly mea-
suring the mean frequency of a single unit discharge is that
it may be a reflection of the true resting central sympathetic
output to the periphery. This is because it allows quantifi-
cation from specific units with demonstrable vasoconstrictor
function without interference from other uncharacterized
units. In addition, it can avoid the inclusion of recruited
units, which could otherwise be counted during the record-
ing of MSNA bursts. Finally, although the technique of
microneurography is selective for the particular unit(s)
studied, under resting conditions the variability between
repeat recordings of both s-MSNA and MSNA is 8%
(16).
In this study we measured both the resting mean fre-
quency of multiunit MSNA bursts and single unit dis-
charge. Qualitatively, both measures responded to reflex
maneuvers in a manner that reflected their involvement in
peripheral vascular control. The results obtained from
MSNA recordings in this study were similar to those
previously published in age-comparable hypertensive sub-
jects (15,16,25,26,28). This can be considered a reflection of
the stringent study protocol and the attempts to avoid
confounding factors. As previously discussed (16), it is
known that many biological factors can influence sympa-
thetic output such as age, obesity and severity of hyperten-
sion, as well as environmental factors including dietary
sodium intake, alcohol, nicotine and exercise. Thus subjects
in the two groups were closely matched for biological
variables and were studied under the same laboratory con-
ditions. Although there was a significant difference in LVM
between the two groups, there was a degree of overlap in the
data. This relates, in part, to the variability of left ventricular
internal diameter and the requirement of an increase in wall
thickness for a patient to be considered as having LVH.
This overlap could not be avoided, as it was important that
subjects were matched for biological variables and not
excluded on the basis of cavity or wall dimensions. However,
even if we hypothesize that the EHT group had some
degree of LVH (to explain the overlap), it remains valid that
the EHT LVH group with a greater degree of LVH have
greater sympathetic activation. In fact, this is further sup-
ported by the fact that there was a positive correlation
between LVMI and sympathetic nerve activity.
Main findings. In this study, the resting mean discharge
frequency of s-MSNA per 100 cardiac beats in the patients
with EHT LVH was significantly greater (by about 46%)
than that in the EHT group. Assessment from multiunit
MSNA bursts revealed that the EHT  LVH group still
had about 31% greater sympathetic activity than the EHT
group. Although there was a similar trend regarding the
mean discharge frequency per minute of both measures of
sympathetic activity, the differences did not reach statistical
significance. This increase in both single unit and multiunit
sympathetic discharge demonstrates two potential mecha-
nisms for central sympathetic regulation. First, increased
s-MSNA represents a true increase in the discharge fre-
quency of central sympathetic neurons. Second, increased
MSNA represents central activation as well as reflex-based
increases (fiber recruitment) in sympathetic activity.
In interpreting these results, it is important to take into
consideration that some of the subjects with LVH were on
antihypertensive medication, some of which can lower heart
rate. It is well known that differences in the pulse interval
can affect the assessment of mean sympathetic discharge
frequency (24). Thus, considering the data over 100 heart
beats to allow for differences in resting heart rate, assess-
ment of both MSNA and s-MSNA demonstrated clear
differences between the groups. Furthermore, if one consid-
ers only those subjects not receiving antihypertensive ther-
apy, then the group resting heart rates were similar, and the
overall findings of sympathetic discharge were unaltered. In
addition, it has been reported that beta-blockers have a
variable effect on sympathetic discharge. Acute intravenous
administration can increase sympathetic discharge, presum-
ably as a result of acute blood pressure lowering and
baroreceptor reflex activation. However, chronic adminis-
tration, as in this study, with agents such as atenolol (29)
and metoprolol (30) may, respectively, have either no effect
on or reduce the resting mean frequency of sympathetic
discharge in EHT. Also, treatment with angiotensin-
converting enzyme inhibitors in hypertension has been
shown to have either no effect or decrease sympathetic nerve
traffic (31,32). Therefore, the increased activity in EHT 
LVH was not attributable to antihypertensive treatment
and, in fact, was still apparent despite the use of agents that
may have attenuated the group differences, thus adding
further weight to the findings.
Previous investigators have suggested a positive correla-
tion between MSNA and the severity of hypertensive
disease (15). More recently, we have shown that patients
with moderate to severe hypertension had either lower or
equal sympathetic output compared with matched groups
with milder hypertension, depending on whether single
units or multiunits were examined (16). There are a number
of reasons that may account for these different findings.
First, blood pressure classification differed between the
studies, the former using an arbitrary classification and the
latter using the JNC-VI classification (21). Secondly, we
have shown that the ability to record neural activity from a
single sympathetic unit allows further insight into central
command, as it allows a true assessment of central sympa-
thetic discharge frequency. Thus, using a combination of
single and multiunit assessment may have allowed further
characterization of the hypertensive subjects. Finally, and
perhaps most importantly, subjects with severe hypertension
in the former study had a high LVMI, whereas, in the latter
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study, LVH was excluded. Thus, the apparent contradictory
results in these two studies can be explained in a manner
entirely consistent with the current findings. The results of
this investigation suggest that the occurrence of LVH in
EHT is associated with an increase in magnitude of the
sympathetic hyperactivity compared with that in subjects
without LVH.
These findings also help to reconcile differing reports on
sympathetic hyperactivity in hypertension. On the one hand
it has been reported that peripheral sympathetic hyperactiv-
ity mainly occurred in borderline/mild hypertension
(16,25,27,33) as well as in younger patients (11,13,27).
These findings have provided support to the theory that the
onset of hypertension is associated with sympathetic hyper-
activity, while, eventually, the severity of hypertension is
maintained, in part, by the occurrence of end-organ struc-
tural changes (11,34). On the other hand, marked periph-
eral sympathetic hyperactivity has also been reported in
patients with severe hypertension (15). The finding that
established hypertension complicated by LVH is associated
with a more marked sympathetic hyperactivity than uncom-
plicated hypertension of equal severity suggests the possi-
bility of different subgroups within the hypertensive popu-
lation. Given that arterial pressure is modulated by various
central, reflex, hormonal and structural changes as well as by
sympathetic drive (11,12,34), it may be reasonable to
postulate that patients destined to develop LVH or vascular
hypertrophy are more likely to maintain, or further increase,
their marked sympathetic hyperactivity. In support of this,
catecholamines have been shown experimentally to have
trophic properties on cardiac myocytes (35) and in the intact
animal heart (36). Also, in human studies, indexes of LVM
have tended to correlate with plasma norepinephrine values
(37) and cardiac noradrenaline spillover (38). However, we
must also consider an opposing viewpoint, that is, the
presence of LVH may lead to the increase in peripheral
sympathetic activity. This situation could potentially arise
via the altered stimulation of cardiac afferent fibers in the
hypertrophied (“stiff”) ventricle. This maybe less likely, as
recent experimental evidence suggests that isolated ventric-
ular distension has only a small effect on systemic perfusion
pressure (vascular resistance) until distension is excessive
(39). Also, a stiffer left ventricle could lead to atrial
distension, but stimulation of mechanoreceptors in the walls
of the atria and vein-atrial junctions has been shown not to
affect the discharge in peripheral sympathetic nerves (40).
Study limitations. The fundamental problem of all studies
of human autonomic control is the constraint imposed by
the limited techniques available to actually quantify sym-
pathetic activity. Although microneurography has been
considered the only technique available to “directly” record
sympathetic activity in human subjects, recordings are made
from a peripheral nerve. It is known that reflex activation of
the sympathetic system is heterogeneous in nature; however,
this study was performed in the baseline resting state. In
addition, although elegant techniques for the assessment of
cardiac sympathetic function utilizing norepinephrine spill-
over are available, by their invasive nature they still have
methodologic constraints. Importantly, however, evidence
does suggest that measures of cardiac norepinephrine spill-
over do correlate well with recordings of peripheral sympa-
thetic nerve activity (41). One final point to remember is
that this was a cross-sectional study, which, although it
implies an association, gives no direct evidence of causality.
There are many additional factors known to be important in
the development of LVH, but, in light of the current
findings, the occurrence of LVH needs to be considered in
future studies involving sympathetic assessment in hyper-
tensive disease.
Conclusions. This is the first evidence that, in patients
with moderate to severe EHT, the presence of LVH is
associated with higher resting sympathetic discharge, evi-
denced by both an increase in unitary firing frequency and
by fiber recruitment. This supports the hypothesis that
central sympathetic hyperactivity may be a factor in the
development of hypertensive LVH.
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